Joe
@Gantosj
Equity market consultant. Technical Analysis Trader with over 25 years of experience. #Biotech Deep dive research. Biotech Trading Analyst @ChimeraResearch
From Jan-Mar 2021 was last time that the $XBI outperformed the $SPY $NDX & $IWM Since then, $XBI underperformance has continued to widen & leaving most #biotech investors waiting for the inflection point that would move the sector back where it belongs!
And $VLTLF $LIB is breaking out the 200MA on a huge volume both in the US & Canada!!! Is it the inflection point $VLT:F's investors were waiting for? Let's see what they have in the next few weeks!
Strong performance for $VLTLF $LIB today, up 21.21% on robust volume... 397K in the US and over 656K in Canada! It certainly appears that sophisticated investors are stepping in and loading up, signaling renewed confidence and momentum in the stock. #StockMarket #Investing…
$VLTLF making a 50% move from yesterday’s low to today’s high…. Some strong news flowing and much more to come. It would take 96 units doing 100k barrels/day to supply the entire US Lithium needs
Strong performance for $VLTLF $LIB today, up 21.21% on robust volume... 397K in the US and over 656K in Canada! It certainly appears that sophisticated investors are stepping in and loading up, signaling renewed confidence and momentum in the stock. #StockMarket #Investing…
Strong performance for $VLTLF $LIB today, up 21.21% on robust volume... 397K in the US and over 656K in Canada! It certainly appears that sophisticated investors are stepping in and loading up, signaling renewed confidence and momentum in the stock. #StockMarket #Investing…
$VLTLF $LIB The street starts digesting yesterday's news & realize the low valuation of this company despite the outstanding progress in the past 14 months reaching the inflection point with its 10K barrels/day unit!
$CNVIF $CNVI.v A surprising reality: In the US, 80%–85% of coronary interventions still rely on traditional X-ray imaging, which often fails to provide surgeons with a complete anatomical view. It’s time for innovation, IVUS/OCT hybrid technology offers a next-level solution,…
#WhyImagingWednesday 💭 New @ConaviMed video series guiding you through the future of imaging in #InterventionalCardiology, from the inside out. X-rays don’t tell the whole story. Watch our first video now! ▶️ Next week: discover what’s missing and how #Conavi goes beyond…
Actually, I like the way $VLTLF bounced back on a very large volume compare to the monthly volume! Things are getting advanced in North-Dakota & waiting for the day they finalize the fine-tuning & get the JV signed! "More than 1,300 DLE cycles have now been completed across six…
Not much out there on $VLTLF but a significant uptick in daily volume over the past week. Hopefully a change in pattern happening.
$EPRX is quickly gaining traction among analysts & is being invited to many #biotech conferences. With Phase 1a data expected in September, these high-profile events could serve as the perfect stage leading into the next major catalyst. Momentum is building, and the timing…
$CNVIF $CNVI.v Is the only commercial provider of a hybrid IVUS+OCT system Conavi is well-positioned to support this clinical shift with the Novasight Hybrid System, which delivers co-registered IVUS and OCT imaging in real time! Byunifying IVUS and OCT in a single platform,…
$CNVIF $CNVI.v We are talking about a newly published study in the highly respected "The American Journal of Cardiology". This kind of recognition speaks volumes about the scientific credibility & potential impact of the company’s work in cardiovascular health.…
$CNVIF $CNVI.v We are talking about a newly published study in the highly respected "The American Journal of Cardiology". This kind of recognition speaks volumes about the scientific credibility & potential impact of the company’s work in cardiovascular health.…
$CNVIF $CNVI Conavi Medical Applauds New American Journal of Cardiology Study Highlighting Importance of Intracoronary Imaging During PCI globenewswire.com/news-release/2…
$CNVIF $CNVI Conavi Medical Applauds New American Journal of Cardiology Study Highlighting Importance of Intracoronary Imaging During PCI globenewswire.com/news-release/2…
📣 Biotech Stock News 07/22 @ Open $CRDL 15% Database Lock for Phase 2 Trial $CNTB 11% Appoints Industry Veteran to Board $STRO 7% Research Collab. to Advance Standards $CGEM 3% Acceptance of Abstracts for Zipalertinib $BIIB 3% Highlighting Progress in Alzheimer's Disease $EHTH…
So, what we should look at, from $CRDL's acute #myocarditis Ph-2 data? The 2 primary outcome measures of the trial, which were evaluated following 12 weeks of double-blind therapy, consist of cardiac MRI parameters: global longitudinal strain and extra-cellular volume, which…
Great move by $CRDL up 16% after the news this morning, locking database from its Ph-2 pericarditis trail & topline results within 2 weeks!
$CRDL’s current valuation barely reflects the significant progress in its #pericarditis program, which has already advanced to Ph-3. If the upcoming Ph-2 #myocarditis data turns out positive, the stock could see a rapid re-rating to the upside. The Ph-3 trial for recurrent…
$CRDL’s current valuation barely reflects the significant progress in its #pericarditis program, which has already advanced to Ph-3. If the upcoming Ph-2 #myocarditis data turns out positive, the stock could see a rapid re-rating to the upside. The Ph-3 trial for recurrent…
So, what we should look at, from $CRDL's acute #myocarditis Ph-2 data? The 2 primary outcome measures of the trial, which were evaluated following 12 weeks of double-blind therapy, consist of cardiac MRI parameters: global longitudinal strain and extra-cellular volume, which…
So, what we should look at, from $CRDL's acute #myocarditis Ph-2 data? The 2 primary outcome measures of the trial, which were evaluated following 12 weeks of double-blind therapy, consist of cardiac MRI parameters: global longitudinal strain and extra-cellular volume, which…
$CRDL There are no FDA-approved drug therapies indicated for the treatment of acute myocarditis. Acute #myocarditis is a potentially life-threatening condition affecting the heart muscle (myocardium) and is characterized by chest pain, shortness of breath, fatigue, rapid or…
$CRDL There are no FDA-approved drug therapies indicated for the treatment of acute myocarditis. Acute #myocarditis is a potentially life-threatening condition affecting the heart muscle (myocardium) and is characterized by chest pain, shortness of breath, fatigue, rapid or…
$CRDL Topline results are expected within the next two weeks. Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx(TM) in Acute #Myocarditis newsfilecorp.com/release/259556
$CRDL Topline results are expected within the next two weeks. Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx(TM) in Acute #Myocarditis newsfilecorp.com/release/259556
Things are starting to get real. The FDA has now acknowledged a connection between COVID-19 vaccines and the increase in pericarditis and myocarditis cases among young people. On the bright side, it's great to see $CRDL making solid progress with their #Pericarditis study,…
.@US_FDA recently issued class safety warnings for myocarditis and pericarditis from COVID mRNA vaccines.
$EPRX is down today on a very tiny volume, likely a case of price manipulation or classic “tree shaking” to scoop up shares at a discount. For those who’ve done their due diligence and recognize the tremendous upside in $EPRX, this pullback could be a strategic buying…
$EPRX is one of the best runners in 2025 so far with over 195% from the 52W-low U$2.20 to 52W-H $6.20 Now, it's flagging, preparing for the next move. Waiting for the next data release, it's very important point to see how impressive was cohort-8 dose, to choose it for the next…
$CNVIF $CNVI is showing strength, resisting price manipulation with a lower open on light volume today. This has attracted long-term investors to buy the dip, forming a potential "Bullish Engulfing Candlestick" & printing a new higher high, C$0.54. Next is the 200MA around $0.70…
As expected, $CNVI.v is moving fast upwards to C$0.50 after breaking out the consolidation line at C$0.40 Next target is the C$0.60 line followed by the 200MA around C$0.70 Meanwhile in the US $CNVIF is moving to U$0.355 to get closer to the Canadian valuation. Next U$0.42
$VLTF $LIB just the starting point of a very long run 10x from here easy. Total tech breakthrough in Lithium extraction at a fraction of cost with small CAPEX.
The day the street understands that $VLTLF $LIB's DLE is the cheapest way in the world to extract #Lithium, which is a critical mineral for the US, where China controls 90% of the world production, then US Government will push $VLTLF & support their DEL
The day the street understands that $VLTLF $LIB's DLE is the cheapest way in the world to extract #Lithium, which is a critical mineral for the US, where China controls 90% of the world production, then US Government will push $VLTLF & support their DEL
$VLTLF this is a massive tech breakthrough in lithium extraction, lower cost than any lithium mine and helps oil producers cut costs. This will deliver a monster stock return quickly.